FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Tom Ganten

Research Profile

Chemicals & Drugs

Disorders

Anatomy

Phenomena

Blotting, Western

Concepts & Ideas

Treatment Outcome

Co-author Network

Publications

TOP 3
Katharina Esser-Nobis; Tom M Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Darius Moradpour; François Penin; Stephen J Polyak; Inés Romero-Brey; Peter Schemmer; Paul Schnitzler; Wolfgang Stremmel; Ralf Bartenschlager; Marco Binder; Christoph Eisenbach; Volker Lohmann
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Xu Dai; Tom M Ganten; Karolin Höh; Heinz-Peter Schlemmer; Bernhard Schmidt; Ke Xu; Marika Ganten
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Ronald Koschny; Wolfgang Stremmel; Daniel Gotthardt; Dirk Jaeger; Christiane Koehler; Tom M Ganten
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Tom Ganten (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Katharina Esser-Nobis; Tom M Ganten; Jérôme Gouttenoire; Christian Harak; Rahel Klein; Darius Moradpour; François Penin; Stephen J Polyak; Inés Romero-Brey; Peter Schemmer; Paul Schnitzler; Wolfgang Stremmel; Ralf Bartenschlager; Marco Binder; Christoph Eisenbach; Volker Lohmann
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Hepatology (Baltimore, Md.) 2013;57(3):953-63.
2013: Xu Dai; Tom M Ganten; Karolin Höh; Heinz-Peter Schlemmer; Bernhard Schmidt; Ke Xu; Marika Ganten
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
European journal of radiology 2013;82(2):327-34.
2013: Ronald Koschny; Wolfgang Stremmel; Daniel Gotthardt; Dirk Jaeger; Christiane Koehler; Tom M Ganten
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Oncology 2013;84(1):6-13.
2012: Christof M Sommer; Ulrike Stampfl; Juergen Weitz; Peter Sauer; Nadine Bellemann; Tom M Ganten; Theresa L Gockner; Hans U Kauczor; Boris Radeleff
Technical and clinical outcome of transjugular intrahepatic portosystemic stent shunt: bare metal stents (BMS) versus viatorr stent-grafts (VSG).
European journal of radiology 2012;81(9):2273-80.
2012: Arianeb Mehrabi; Morva Tahmasbi Rad; Nuh N Rahbari; Mahmoud Sadeghi; Jan Schmidt; Majid Esmaeilzadeh; Hamidreza Fonouni; Mohammad Golriz; Mohammadreza Hafezi; Ali Majlesara; Tom M Ganten
The role of HBIg as hepatitis B reinfection prophylaxis following liver transplantation.
Langenbeck's archives of surgery / Deutsche Gesellschaft für Chirurgie 2012;397(5):697-710.
2012: Boris Radeleff; C M Sommer; Ulrike Stampfl; N Bellemann; Robert Ehehalt; Tom M Ganten; K Hoffmann; Hans-Ulrich Kauczor
[Transarterial ablation of hepatocellular carcinoma. Status and developments].
Der Radiologe 2012;52(1):44-55.
2012: Stefan O Schönland; A V Kristen; Jörg Beimler; N Blank; Tom M Ganten; Ute Hegenbart
[Systemic amyloidoses].
Der Internist 2012;53(1):51-64.
2011: Katrin Hoffmann; Boris A Radeleff; Peter Schirmacher; Jan Schmidt; Markus W Büchler; Tom M Ganten; Norbert Hillebrand; Ulf Hinz; Peter Schemmer
Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis.
Clinical transplantation 2011;25(5):E541-51.
2010: Ronald Koschny; Heidrun Holland; Jaromir Sykora; Hande Erdal; Wolfgang Krupp; Manfred Bauer; Ulrike Bockmuehl; Peter Ahnert; Jürgen Meixensberger; Wolfgang Stremmel; Henning Walczak; Tom M Ganten
Bortezomib sensitizes primary human esthesioneuroblastoma cells to TRAIL-induced apoptosis.
Journal of neuro-oncology 2010;97(2):171-85.
2010: S Brost; Jürgen J Wenzel; Tom M Ganten; M Filser; C Flechtenmacher; S Boehm; A Astani; Wolfgang Jilg; M Zeier; Paul Schnitzler
Sporadic cases of acute autochthonous hepatitis E virus infection in Southwest Germany.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2010;47(1):89-92.
2009: Ronald Koschny; Jan Schmidt; Tom M Ganten
Beyond Milan criteria--chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis.
Clinical transplantation 2009;23 Suppl 21():49-60.
2009: Tom M Ganten; Jaromir Sykora; Ronald Koschny; Emanuela Batke; Sebastian Aulmann; Ulrich Mansmann; Wolfgang Stremmel; Hans-Peter Sinn; Henning Walczak
Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Journal of molecular medicine (Berlin, Germany) 2009;87(10):995-1007.
2008: Marika Ganten; Marc-André Weber; Tom M Ganten
[Cellular mechanisms of tumor response: clinical demands].
Der Radiologe 2008;48(9):820-31.
2008: Susanne Kleber; Ignacio Sancho-Martinez; Benedict Wiestler; Alexandra Beisel; Christian Gieffers; Oliver Hill; Meinolf Thiemann; Wolf Mueller; Jaromir Sykora; Andreas Kuhn; Nina Schreglmann; Elisabeth Letellier; Cecilia Zuliani; Stefan Klussmann; Marcin Teodorczyk; Hermann-Josef Gröne; Tom M Ganten; Holger Sültmann; Jochen Tüttenberg; Andreas von Deimling; Anne Regnier-Vigouroux; Christel Herold-Mende; Ana Martin Villalba
Yes and PI3K bind CD95 to signal invasion of glioblastoma.
Cancer cell 2008;13(3):235-48.
2007: Heidrun Holland; Ronald Koschny; Wolfgang Krupp; Jürgen Meixensberger; Manfred Bauer; Ralf Schober; Holger Kirsten; Tom M Ganten; Peter Ahnert
Cytogenetic and molecular biological characterization of an adult medulloblastoma.
Cancer genetics and cytogenetics 2007;178(2):104-13.
2007: Ronald Koschny; Henning Walczak; Tom M Ganten
The promise of TRAIL--potential and risks of a novel anticancer therapy.
Journal of molecular medicine (Berlin, Germany) 2007;85(9):923-35.
2007: Nikolaus Gassler; Wilfried Roth; Benjamin Funke; Armin Schneider; Frank Herzog; J J W Tischendorf; Kerstin Grund; Roland Penzel; Ignacio G Bravo; John M Mariadason; Volker Ehemann; Jaromir Sykora; Tobias L Haas; Henning Walczak; Tom M Ganten; Hanswalter Zentgraf; Peter Erb; Angel Alonso; Frank Autschbach; Peter Schirmacher; Ruth Knüchel; Jürgen Kopitz
Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing.
Gastroenterology 2007;133(2):587-98.
2007: Ronald Koschny; Heidrun Holland; Jaromir Sykora; Tobias L Haas; Martin Sprick; Tom M Ganten; Wolfgang Krupp; Manfred Bauer; Peter Ahnert; Jürgen Meixensberger; Henning Walczak
Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3403-12.
2007: Ronald Koschny; Tom M Ganten; Jaromir Sykora; Tobias L Haas; Martin Sprick; Armin Kolb; Wolfgang Stremmel; Henning Walczak
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window.
Hepatology (Baltimore, Md.) 2007;45(3):649-58.
2007: Tom M Ganten; E Aravena; Jaromir Sykora; Ronald Koschny; J Mohr; Jochen Rudi; Wolfgang Stremmel; Henning Walczak
Helicobacter pylori-induced apoptosis in T cells is mediated by the mitochondrial pathway independent of death receptors.
European journal of clinical investigation 2007;37(2):117-25.
2006: Tom M Ganten; Ronald Koschny; Jaromir Sykora; Henning Schulze-Bergkamen; Peter Büchler; Tobias L Haas; Manuela B Schader; Andreas Untergasser; Wolfgang Stremmel; Henning Walczak
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2640-6.
2005: Tom M Ganten; Ronald Koschny; Tobias L Haas; Jaromir Sykora; Min Li-Weber; Kerstin Herzer; Henning Walczak
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL.
Hepatology (Baltimore, Md.) 2005;42(3):588-97.
2005: Kerstin Herzer; Tom M Ganten; Henning Schulze-Bergkamen; Anne Grosse-Wilde; Ronald Koschny; Peter H Krammer; Henning Walczak
Transforming growth factor beta can mediate apoptosis via the expression of TRAIL in human hepatoma cells.
Hepatology (Baltimore, Md.) 2005;42(1):183-92.
2004: Tom M Ganten; Tobias L Haas; Jaromir Sykora; Heiko Stahl; Martin Sprick; Stefanie C Fas; Andreas Krueger; Markus A Weigand; Anne Grosse-Wilde; Wolfgang Stremmel; Peter H Krammer; Henning Walczak
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
Cell death and differentiation 2004;11 Suppl 1():S86-96.